Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors

TAS-115 is a novel MET, VEGFR, FMS and PDGFR inhibitor, developed to improve the continuity of drug administration with a relatively short half-life. We assessed its tolerability, safety, pharmacokinetics, efficacy, and pharmacodynamics in patients with solid tumors. This open-label, dose-escalation...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Matsubara, Nobuaki, Kawai, Akira, Naka, Norifumi, Takahashi, Shunji, Uemura, Hiroji, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340670/
https://www.ncbi.nlm.nih.gov/pubmed/31820255
http://dx.doi.org/10.1007/s10637-019-00859-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340670/
https://www.ncbi.nlm.nih.gov/pubmed/31820255
http://dx.doi.org/10.1007/s10637-019-00859-4

Ejemplares similares